Assessing the Potency of (Company's Proprietary Compound) on Orthotopic Patient Derived Glioblastoma Tumors

Preliminary experiments to determine whether treatment toxicity is apparent. RT + TMZ + CXCR4i. Administer CXCR4i for 2 days in advance of initiating RT + TMZ regimen, and continue administration of CXCR4i during 5 days of RT + TMZ administration, as well as for one week following completion of RT + TMZ. Observe and weigh mice daily, during and for one week after completion of treatment. This experiment and analysis should require 21 days and will use 5 mice. CCNU +/- CXCR4i. Administer CCNU 1x at 30 mg/kg (i.p.), with and without CXCR4i administered daily for 2 weeks, with first day of CXCR4i administration on day of CCNU administration. Observe and weigh mice daily during and for one week following completion of treatment. This experiment and analysis should require 21 days and will use 10 mice.